TITLE

Coxibs and cardiovascular risk

AUTHOR(S)
Pijak, Michal R.; Huzicka, Igor; Gazdik, Frantisek
PUB. DATE
October 2005
SOURCE
CMAJ: Canadian Medical Association Journal;10/11/2005, Vol. 173 Issue 8, p852
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
Presents a letter to the editor in response to the article "New Restrictions on Celecoxib (Celebrex) Use and the Withdrawal of Valdecoxib (Bextra)," by Jill Cotter and Eric Wooltorton in the 2005 issue of the "Canadian Medical Association Journal."
ACCESSION #
18415256

 

Related Articles

  • Coxibs and cardiovascular risk. Zaidi, Syed A. H. // CMAJ: Canadian Medical Association Journal;10/11/2005, Vol. 173 Issue 8, p852 

    Presents a letter to the editor in response to the article "New Restrictions on Celecoxib (Celebrex) Use and the Withdrawal of Valdecoxib (Bextra)," by Jill Cotter and Eric Wooltorton in the 2005 issue of the "Canadian Medical Association Journal."

  • Coxibs and cardiovascular risk. Allen, Michael J.; McLean-Veysey, Pamela; Fleming, Isobel // CMAJ: Canadian Medical Association Journal;10/11/2005, Vol. 173 Issue 8, p853 

    Presents a letter to the editor in response to the article "New Restrictions on Celecoxib (Celebrex) Use and the Withdrawal of Valdecoxib (Bextra)," by Jill Cotter and Eric Wooltorton in the 2005 issue of the "Canadian Medical Association Journal."

  • Celecoxib versus Diclofenac and Omeprazole to Prevent Recurrent Ulcer Bleeding. Nurmohamed, Michael T.; Lems, Willem F. // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2464 

    A letter to the editor is presented in response to the article "Celecoxib versus diclofenac plus omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis," by F. K. L. Chan and colleagues in the December 26, 2002 issue.

  • Celecoxib versus Diclofenac and Omeprazole to Prevent Recurrent Ulcer Bleeding. Lanas, Angel // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2464 

    A letter to the editor is presented in response to the article "Celecoxib versus diclofenac plus omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis," by F. K. L. Chan and colleagues in the December 26, 2002 issue.

  • Celecoxib versus Diclofenac and Omeprazole to Prevent Recurrent Ulcer Bleeding. McKeogh, Donogh F. // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2464 

    A letter to the editor is presented in response to the article "Celecoxib versus diclofenac plus omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis," by F. K. L. Chan and colleagues in the December 26, 2002 issue.

  • Celecoxib versus Diclofenac and Omeprazole to Prevent Recurrent Ulcer Bleeding. Chan, Francis K. L. // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2464 

    A response by Francis K. L. Chan to a letter to the editor about his article "Celecoxib versus diclofenac plus omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis" in the December 26, 2002 issue is presented.

  • Celecoxib versus Diclofenac and Omeprazole to Prevent Recurrent Ulcer Bleeding. Graham, David Y. // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2464 

    A response by David Y. Graham to a letter to the editor about his article "Celecoxib versus diclofenac plus omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis" in the December 26, 2002 issue is presented.

  • Cardiovascular Risk Associated with Celecoxib. Brophy, James M. // New England Journal of Medicine;6/23/2005, Vol. 352 Issue 25, p2648 

    This article presents a letter to the editor in response to "Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention," by D. S. Solomon, J. J. V. McMurray et al. in the March 17, 2005 issue.

  • Cardiovascular Risk Associated with Celecoxib. Solomon, Scott D.; Wittes, Janet; McMurray, John // New England Journal of Medicine;6/23/2005, Vol. 352 Issue 25, p2648 

    This article presents a reply to letters to the editors in response to "Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention," by D.S. Solomon, J.J.V. McMurray et al. in the March 17, 2005 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics